Ticker Details
Atara Biotherapeutics, Inc. Atara Biotherapeutics Inc is engaged in the development of pharmaceutical products. The company's focus lies on developing therapies addressing serious-life threatening diseases in the United States.
IPO Date:	October 16, 2014
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$86.95M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.65 | 4.27%
Avg Daily Range (30 D):	$0.47 | 4.58%
Avg Daily Range (90 D):	$0.38 | 5.42%

Institutional Daily Volume
Avg Daily Volume:	.13M
Avg Daily Volume (30 D):	.08M
Avg Daily Volume (90 D):	1.08M

Trade Size
Avg Trade Size (Sh.):	27
Avg Trade Size (Sh.) (30 D):	69
Avg Trade Size (Sh.) (90 D):	91

Institutional Trades
Total Institutional Trades:	2,727
Avg Institutional Trade:	$2.22M
Avg Institutional Trade (30 D):	$.58M
Avg Institutional Trade (90 D):	$1.21M
Avg Institutional Trade Volume:	.01M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2M
Avg Closing Trade (30 D):	$.58M
Avg Closing Trade (90 D):	$.58M
Avg Closing Volume:	6.18K

News

May 19, 2026 @ 10:22 PM ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, E... Source: Rosen Law Firm

May 18, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Atara Biot... Source: Bronstein, Gewirtz & Grossman Llc

May 14, 2026 @ 6:45 PM DEADLINE ALERT for ATRA, COTY, SMCI, IBRX: Law Off... Source: Law Offices Of Howard G. Smith

May 14, 2026 @ 4:00 PM Bronstein, Gewirtz & Grossman LLC Urges Atara Biot... Source: Bronstein, Gewirtz & Grossman Llc

May 14, 2026 @ 2:34 AM ATRA Investors Have Opportunity to Lead Atara Biot... Source: The Schall Law Firm

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.76	$-.29	$-.35
Diluted EPS	$-.78	$-.29	$-.36
Revenue	$23.14M	$.52M	$1.6M
Gross Profit
Net Income / Loss	$-9.47M	$-4.15M	$-3.41M
Operating Income / Loss	$-6.31M	$-3.37M	$-2.56M
Cost of Revenue
Net Cash Flow	$-5.51M	$M	$2.74M
PE Ratio

Splits
Jun 20, 2024	1:25